Crinetics Pharma (CRNX)
NASDAQ:CRNX
Want to see CRNX full AI Analyst Report?
CRNX Stock Chart & Stats
$41.00
-$0.61(-1.22%)
At close: 4:00 PM EST
$41.00
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$25.83 - $57.99
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.28M
Market Cap
$3.66B
Enterprise Value$3.76B
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$47.85M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 11, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.14
Shares Outstanding105,440,210
10 Day Avg. Volume1,700,799
30 Day Avg. Volume1,278,531
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue207.97
Enterprise Value/Gross Profit210.30
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$86.00Price Target Upside109.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.8
Revenue Forecast (FY)$68.57M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumEarly commercial launch metrics and stronger-than-expected initial sales for Palsonify, combined with growing prescriber adoption and favorable payer coverage, support potential revenue upside as uptake broadens.
Pipeline DiversificationAdvancement of multiple late-stage programs, a seamless Phase 2/3 approach for atumelnant, and initiation of a new drug-conjugate candidate broaden the pipeline and create multiple future value drivers beyond the lead product.
Regulatory ProgressA positive CHMP opinion for Palsonify increases the prospect of European marketing authorization, which would expand the drug's geographic reach and commercial opportunity.
Bears Say
Financial RunwayHigh cash burn relative to available cash raises the probability of needing additional capital, which could dilute shareholders or constrain funding for development and commercialization.
Market Adoption BarriersCost pressures and insufficient education among providers and patients may lead many diagnosed individuals to forgo active treatment, limiting market penetration for the new therapy.
Revenue PredictabilityA potentially lumpy launch cadence and limited monthly trend visibility create uncertainty around near-term revenue predictability and complicate forecasting for investors.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $25.83 and its highest was $57.99 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $3.66B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on May 07, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.22.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 105,440,210 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went down -13.819%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.00 (109.76% Upside)
$86.00 (109.76% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.89%
12-Months-Change
Fundamentals
Return on Equity
-43.96%
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Company Deck
CRNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$86.00
▲(109.76% Upside)
Technical Analysis
Ligand Pharma
―
Ultragenyx Pharmaceutical
―
Apellis Pharmaceuticals
―
―
Kymera Therapeutics
―
Ownership Overview
1.92% Insiders
38.15% Mutual Funds
42.87% Other Institutional Investors
1.77% Public Companies and
Individual Investors